Further investigations into the relative contribution of the intrinsic pathway during an active thrombotic event, in anticipation of the novel FXI and FXII inhibiting agents, could, nevertheless, be of great value to this difficult to treat thrombosis population. The gene discussed is F11; the disease is deep vein thrombosis.